Medivir
Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer, aiming to improve life for cancer patients through transformative drugs. They focus on cancers of high unmet medical need and leverage collaborations with academic and industrial partners to advance their projects.
Industries
Nr. of Employees
medium (51-250)
Medivir
Patents
Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
US-12303521-B2
View DetailsCancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
US-12221459-B2
View Details
Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
US-12303521-B2
View DetailsCancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
US-12221459-B2
View DetailsProducts
Fostroxacitabine bralpamide (fostrox)
Oral nucleotide DNA polymerase inhibitor in clinical development for hepatocellular carcinoma; monotherapy (Phase I) and combination study (Phase II).
Remetinostat
Topical HDAC inhibitor under licensing for cutaneous T‑cell lymphoma and other skin cancers.
MIV-711
Oral cathepsin K inhibitor developed for osteoarthritis and related indications; includes investigator‑sponsored clinical evaluations.
Birinapant / IGM‑9427
Intravenous SMAC mimetic in early clinical development for solid tumors (Phase I).
Xerclear (Zoviduo)
Combination topical product containing an antiviral and a corticosteroid marketed for labial herpes.
USP‑7 program
Preclinical oncology program developed in partnership with an external research organization.
Fostroxacitabine bralpamide (fostrox)
Oral nucleotide DNA polymerase inhibitor in clinical development for hepatocellular carcinoma; monotherapy (Phase I) and combination study (Phase II).
Remetinostat
Topical HDAC inhibitor under licensing for cutaneous T‑cell lymphoma and other skin cancers.
MIV-711
Oral cathepsin K inhibitor developed for osteoarthritis and related indications; includes investigator‑sponsored clinical evaluations.
Birinapant / IGM‑9427
Intravenous SMAC mimetic in early clinical development for solid tumors (Phase I).
Xerclear (Zoviduo)
Combination topical product containing an antiviral and a corticosteroid marketed for labial herpes.
USP‑7 program
Preclinical oncology program developed in partnership with an external research organization.
Services
Collaborative research partnerships, licensing deals and joint development agreements to advance drug candidates from research to market.
Collaborative research partnerships, licensing deals and joint development agreements to advance drug candidates from research to market.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Small-molecule medicinal chemistry
- Preclinical pharmacology and animal models
Key Technologies
- Small-molecule therapeutics
- Nucleotide DNA polymerase inhibitors
- HDAC inhibitors
- Cathepsin K inhibitors